abobotulinumtoxinA
Homatropine may increase the anticholinergic activities of Botulinum Toxin Type A.
Aclidinium
Homatropine may increase the anticholinergic activities of Aclidinium.
Alfentanil
The risk or severity of adverse effects can be increased when Homatropine is combined with Alfentanil.
Advertisement
Alphaprodine
The risk or severity of adverse effects can be increased when Homatropine is combined with Alphaprodine.
Ambenonium
The therapeutic efficacy of Homatropine can be decreased when used in combination with Ambenonium.
Atracurium
The risk or severity of adverse effects can be increased when Atracurium is combined with Homatropine.
Advertisement
Atracurium Besylate
The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Homatropine.
Atropine
The risk or severity of adverse effects can be increased when Atropine is combined with Homatropine.
Benactyzine
The risk or severity of adverse effects can be increased when Benactyzine is combined with Homatropine.
Advertisement
Bendroflumethiazide
The serum concentration of Bendroflumethiazide can be increased when it is combined with Homatropine.
Benztropine
The risk or severity of adverse effects can be increased when Benzatropine is combined with Homatropine.
Biperiden
The risk or severity of adverse effects can be increased when Biperiden is combined with Homatropine.
Botulinum Toxin Type A
Homatropine may increase the anticholinergic activities of Botulinum Toxin Type A.
Buprenorphine
The risk or severity of adverse effects can be increased when Homatropine is combined with Buprenorphine.
Butorphanol
The risk or severity of adverse effects can be increased when Homatropine is combined with Butorphanol.
Butylscopolamine
The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Homatropine.
Chlorothiazide
The serum concentration of Chlorothiazide can be increased when it is combined with Homatropine.
Chlorphenoxamine
The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Homatropine.
Chlorthalidone
The serum concentration of Chlorthalidone can be increased when it is combined with Homatropine.
Codeine
The risk or severity of adverse effects can be increased when Homatropine is combined with Codeine.
Codeine Anhydrous
The risk or severity of adverse effects can be increased when Homatropine is combined with Codeine.
CODEINE POLISTIREX
The risk or severity of adverse effects can be increased when Homatropine is combined with Codeine.
Cyclopenthiazide
The serum concentration of Cyclopenthiazide can be increased when it is combined with Homatropine.
Cyclopentolate
The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Homatropine.
Darifenacin
The risk or severity of adverse effects can be increased when Darifenacin is combined with Homatropine.
Demecarium
The therapeutic efficacy of Homatropine can be decreased when used in combination with Demecarium.
Desloratadine
The risk or severity of adverse effects can be increased when Desloratadine is combined with Homatropine.
Dexetimide
The risk or severity of adverse effects can be increased when Dexetimide is combined with Homatropine.
Dextromoramide
The risk or severity of adverse effects can be increased when Homatropine is combined with Dextromoramide.
Dezocine
The risk or severity of adverse effects can be increased when Homatropine is combined with Dezocine.
Dicyclomine
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Homatropine.
Dihydrocodeine
The risk or severity of adverse effects can be increased when Homatropine is combined with Dihydrocodeine.
Diphenoxylate
The risk or severity of adverse effects can be increased when Homatropine is combined with Diphenoxylate.
Distigmine
The therapeutic efficacy of Homatropine can be decreased when used in combination with Distigmine.
Donepezil
The therapeutic efficacy of Homatropine can be decreased when used in combination with Donepezil.
Echothiophate
The therapeutic efficacy of Homatropine can be decreased when used in combination with Echothiophate.
Edrophonium
The therapeutic efficacy of Homatropine can be decreased when used in combination with Edrophonium.
Eluxadoline
Homatropine may increase the constipating activities of Eluxadoline.
Ethylmorphine
The risk or severity of adverse effects can be increased when Homatropine is combined with Ethylmorphine.
Fentanyl
The risk or severity of adverse effects can be increased when Homatropine is combined with Fentanyl.
Fesoterodine
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Homatropine.
Galantamine
The therapeutic efficacy of Homatropine can be decreased when used in combination with Galantamine.
Gallamine Triethiodide
The risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Homatropine.
Ginkgo biloba extract
The therapeutic efficacy of Homatropine can be decreased when used in combination with Ginkgo biloba.
Glucagon
The risk or severity of adverse effects can be increased when Homatropine is combined with Glucagon recombinant.
glucagon (rDNA)
The risk or severity of adverse effects can be increased when Homatropine is combined with Glucagon recombinant.
Glycopyrronium
Homatropine may increase the anticholinergic activities of Glycopyrronium.
Heroin
The risk or severity of adverse effects can be increased when Homatropine is combined with Heroin.
Human Secretin
The therapeutic efficacy of Human secretin can be decreased when used in combination with Homatropine.
Hydrochlorothiazide
The serum concentration of Hydrochlorothiazide can be increased when it is combined with Homatropine.
Hydrocodone
The risk or severity of adverse effects can be increased when Homatropine is combined with Hydrocodone.
HYDROCODONE POLISTIREX
The risk or severity of adverse effects can be increased when Homatropine is combined with Hydrocodone.
Hydroflumethiazide
The serum concentration of Hydroflumethiazide can be increased when it is combined with Homatropine.
Hydromorphone
The risk or severity of adverse effects can be increased when Homatropine is combined with Hydromorphone.
Hyoscyamine
The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Homatropine.
incobotulinumtoxinA
Homatropine may increase the anticholinergic activities of Botulinum Toxin Type A.
Indapamide
The serum concentration of Indapamide can be increased when it is combined with Homatropine.
Ipratropium Bromide
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Homatropine.
Ipratropium Bromide Anhydrous
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Homatropine.
Isoflurophate
The therapeutic efficacy of Homatropine can be decreased when used in combination with Isoflurophate.
Levomethadyl
The risk or severity of adverse effects can be increased when Homatropine is combined with Levomethadyl Acetate.
Levorphanol
The risk or severity of adverse effects can be increased when Homatropine is combined with Levorphanol.
Malathion
The therapeutic efficacy of Homatropine can be decreased when used in combination with Malathion.
Mecamylamine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Homatropine.
Mefloquine
The therapeutic efficacy of Homatropine can be decreased when used in combination with Mefloquine.
Memantine
The therapeutic efficacy of Homatropine can be decreased when used in combination with Memantine.
Meperidine
The risk or severity of adverse effects can be increased when Homatropine is combined with Pethidine.
Methadone
The risk or severity of adverse effects can be increased when Homatropine is combined with Methadone.
Methadyl Acetate
The risk or severity of adverse effects can be increased when Homatropine is combined with Methadyl Acetate.
Methantheline
The risk or severity of adverse effects can be increased when Methantheline is combined with Homatropine.
Methixene
The risk or severity of adverse effects can be increased when Metixene is combined with Homatropine.
Methscopolamine
The risk or severity of adverse effects can be increased when Homatropine is combined with Methscopolamine.
Methscopolamine Bromide
The risk or severity of adverse effects can be increased when Homatropine is combined with Methylscopolamine bromide.
Methyclothiazide
The serum concentration of Methyclothiazide can be increased when it is combined with Homatropine.
Metoclopramide
The therapeutic efficacy of Homatropine can be decreased when used in combination with Metoclopramide.
Metolazone
The serum concentration of Metolazone can be increased when it is combined with Homatropine.
Mianserin
Mianserin may increase the anticholinergic activities of Homatropine.
Minaprine
The therapeutic efficacy of Homatropine can be decreased when used in combination with Minaprine.
Mirabegron
The risk or severity of adverse effects can be increased when Homatropine is combined with Mirabegron.
Morphine
The risk or severity of adverse effects can be increased when Homatropine is combined with Morphine.
Nabilone
Homatropine may increase the tachycardic activities of Nabilone.
Nalbuphine
The risk or severity of adverse effects can be increased when Homatropine is combined with Nalbuphine.
Neostigmine
The therapeutic efficacy of Homatropine can be decreased when used in combination with Neostigmine.
Normethadone
The risk or severity of adverse effects can be increased when Homatropine is combined with Normethadone.
O-PHENANTHROLINE
The therapeutic efficacy of Homatropine can be decreased when used in combination with 1,10-Phenanthroline.
Octotropine Methylbromide
The risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Homatropine.
Octylonium
The risk or severity of adverse effects can be increased when Otilonium is combined with Homatropine.
onabotulinumtoxinA
Homatropine may increase the anticholinergic activities of Botulinum Toxin Type A.
Opium
The risk or severity of adverse effects can be increased when Homatropine is combined with Opium.
Orphenadrine
The risk or severity of adverse effects can be increased when Orphenadrine is combined with Homatropine.
Oxitropium
The risk or severity of adverse effects can be increased when Homatropine is combined with Oxitropium.
Oxybutynin
The risk or severity of adverse effects can be increased when Oxybutynin is combined with Homatropine.
Oxycodone
The risk or severity of adverse effects can be increased when Homatropine is combined with Oxycodone.
Oxymorphone
The risk or severity of adverse effects can be increased when Homatropine is combined with Oxymorphone.
Oxyphenonium
The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Homatropine.
Pancuronium
The risk or severity of adverse effects can be increased when Pancuronium is combined with Homatropine.
Pancuronium Bromide
The risk or severity of adverse effects can be increased when Pancuronium is combined with Homatropine.
Paregoric
The risk or severity of adverse effects can be increased when Homatropine is combined with Morphine.
Pentazocine
The risk or severity of adverse effects can be increased when Homatropine is combined with Pentazocine.
Physostigmine
The therapeutic efficacy of Homatropine can be decreased when used in combination with Physostigmine.
Pipecuronium
The risk or severity of adverse effects can be increased when Pipecuronium is combined with Homatropine.
Pirenzepine
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Homatropine.
Pirinitramide
The risk or severity of adverse effects can be increased when Homatropine is combined with Piritramide.
Polythiazide
The serum concentration of Polythiazide can be increased when it is combined with Homatropine.
Potassium Chloride
Homatropine may increase the ulcerogenic activities of Potassium Chloride.
Pramlintide
Pramlintide may increase the anticholinergic activities of Homatropine.
Procyclidine
The risk or severity of adverse effects can be increased when Procyclidine is combined with Homatropine.
Profenamine
The risk or severity of adverse effects can be increased when Ethopropazine is combined with Homatropine.
Propantheline
The risk or severity of adverse effects can be increased when Propantheline is combined with Homatropine.
Propantheline Bromide
The risk or severity of adverse effects can be increased when Propantheline is combined with Homatropine.
Propiverine
The risk or severity of adverse effects can be increased when Propiverine is combined with Homatropine.
Propoxyphene
The risk or severity of adverse effects can be increased when Homatropine is combined with Dextropropoxyphene.
Pyridostigmine
The therapeutic efficacy of Homatropine can be decreased when used in combination with Pyridostigmine.
Pyridostigmine Bromide
The therapeutic efficacy of Homatropine can be decreased when used in combination with Pyridostigmine.
Quinethazone
The serum concentration of Quinethazone can be increased when it is combined with Homatropine.
Quinidine
The risk or severity of adverse effects can be increased when Quinidine is combined with Homatropine.
Remifentanil
The risk or severity of adverse effects can be increased when Homatropine is combined with Remifentanil.
rimabotulinumtoxinB
Homatropine may increase the anticholinergic activities of Botulinum Toxin Type B.
Rivastigmine
The therapeutic efficacy of Homatropine can be decreased when used in combination with Rivastigmine.
Scopolamine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Homatropine.
Scopolamine Hydrobromide
The risk or severity of adverse effects can be increased when Scopolamine is combined with Homatropine.
Secretin
The therapeutic efficacy of Secretin can be decreased when used in combination with Homatropine.
Solifenacin
The risk or severity of adverse effects can be increased when Solifenacin is combined with Homatropine.
Sufentanil
The risk or severity of adverse effects can be increased when Homatropine is combined with Sufentanil.
Sulpiride
Homatropine may increase the anticholinergic activities of Sulpiride.
Tacrine
The therapeutic efficacy of Homatropine can be decreased when used in combination with Tacrine.
Tapentadol
The risk or severity of adverse effects can be increased when Homatropine is combined with Tapentadol.
Tetrahydrocannabinol
Homatropine may increase the tachycardic activities of Dronabinol.
Tiotropium
Homatropine may increase the anticholinergic activities of Tiotropium.
Tolterodine
The risk or severity of adverse effects can be increased when Tolterodine is combined with Homatropine.
Topiramate
The risk or severity of adverse effects can be increased when Homatropine is combined with Topiramate.
Tramadol
The risk or severity of adverse effects can be increased when Homatropine is combined with Tramadol.
Trichlormethiazide
The serum concentration of Trichlormethiazide can be increased when it is combined with Homatropine.
Trihexyphenidyl
The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Homatropine.
Trihexyphenidyl Hydrochloride
The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Homatropine.
Trimethaphan
The risk or severity of adverse effects can be increased when Trimethaphan is combined with Homatropine.
Tropicamide
The risk or severity of adverse effects can be increased when Tropicamide is combined with Homatropine.
Trospium
The risk or severity of adverse effects can be increased when Trospium is combined with Homatropine.
Tubocurarine
The risk or severity of adverse effects can be increased when Tubocurarine is combined with Homatropine.
Umeclidinium
Homatropine may increase the anticholinergic activities of Umeclidinium.
Vecuronium
The risk or severity of adverse effects can be increased when Vecuronium is combined with Homatropine.
